UptonRA. Pharmacokinetic interactions between theophylline and other medications (Part I). Clin Pharmacokinet1991;20: 66–80.
2.
AsmusMJWeinbergerMMMilavetzGMarshikPTeresiMEHendelesL. Apparent decrease in population clearance of theophylline: Implications for dosage. Clin Pharmacol Ther1997;62: 483–9.
3.
EatonDLGallagherEPBammlerTKKunzeKL. Role of cytochrome P4501A2 in chemical carcinogenesis: Implications for human variability in expression and enzyme activity. Pharmacogenetics1995;5: 259–74.
4.
KerbRBrockmöllerJStaffeldtBPlochMRootsI. Single-dose and steady-state pharmacokinetics of hypericin and pseudohypericin. Antimicrob Agents Chemother1996;40: 2087–93.
5.
VandenbogaerdeALGeboesKRCuveeleJFAgostinisPMMerlevedeWJDe WittePA. Antitumour activity of photosensitized hypericin on A431 cell xenografts. Anticancer Res1996;16: 1619–26.